Low Dose GLP-1 After Reaching Goal Weight: What the Evidence Shows

You have reached your goal weight. Now comes the harder question: what happens next?

You could stop the medication and see if the results stick. Many people try this. In trials, most of them regained much of the weight within a year. Or you could stay on a maintenance dose, possibly a lower one, with the aim of keeping the appetite signal turned down with fewer side effects than active treatment dosing.

The evidence is clear about what stopping does. The evidence on staying long-term at a lower dose is limited. This guide walks through what the research shows, what it does not, and what to ask a provider.

The STEP 4 data: Why stopping usually does not work

The STEP 4 trial (published in JAMA in 2021)^[1] started adults on semaglutide, worked them up to 2.4mg weekly over a 20-week run-in, and then split them into two groups for the next 48 weeks.

About one-third of the group was switched to placebo. Over those 48 weeks, they gained back an average of 6.9 percent of their body weight. That is not a failure of willpower or discipline. That is biology. When the GLP-1 signal is removed, appetite tends to return toward its baseline, and for most people that baseline still favors weight gain.

The other two-thirds continued semaglutide at 2.4mg. On average, they kept losing weight, about 7.9 percent more over the same period.^[1]

A separate analysis, the STEP 1 trial extension, followed people who stopped semaglutide after 68 weeks of treatment. One year later, they had regained about two-thirds of the weight they had lost.^[4]

This established the case for continued medication. It did not establish whether continuing at a lower dose would work the same way. The tirzepatide trial below has the same limitation.

Tirzepatide maintenance: SURMOUNT-4

In the SURMOUNT-4 trial^[2], adults took tirzepatide (a GIP and GLP-1 receptor agonist) at their maximum tolerated dose, 10 or 15mg weekly, for 36 weeks and lost an average of 20.9 percent of their body weight. They were then randomized to continue or switch to placebo.

Over the next 52 weeks, the placebo group’s weight rose by an average of 14.0 percent, while the group that continued lost a further 5.5 percent on average. This replicated the STEP 4 finding with a different medication.

Neither trial studied “microdosing” or lower doses for maintenance. The people who kept their results stayed on the same dose they had reached: 2.4mg of semaglutide in STEP 4, and 10 or 15mg of tirzepatide in SURMOUNT-4. The idea that a lower dose may be enough for some people to hold their weight with fewer side effects is a reasonable question to raise with a provider, but it has not been tested in these trials. Results vary, and trial results describe study participants, not what will happen for you.

Long-term safety: The SELECT trial

The largest long-term data for semaglutide in people without diabetes comes from the SELECT trial^[3] (published in the New England Journal of Medicine in 2023). It enrolled 17,604 adults aged 45 or older with existing heart disease and overweight or obesity, and followed them for an average of about 3.3 years (39.8 months).

Key findings:

Semaglutide 2.4mg weekly lowered the rate of heart attack, stroke, or cardiovascular death: 6.5 percent of people on semaglutide had one of these events, compared with 8.0 percent on placebo.^[3]

Side effects were real. Adverse events that led people to stop the drug permanently occurred in 16.6 percent of the semaglutide group and 8.2 percent of the placebo group, mostly digestive problems such as nausea and vomiting.^[3]

The LEADER trial of liraglutide, an earlier medication in the same class, in people with type 2 diabetes followed participants for a median of 3.8 years and also found fewer major cardiovascular events than placebo.^[6]

What this means: the longest large trials of these medications run several years, at full labeled doses, in specific groups of people. We do not have data on 10+ year use at any dose because this generation of medications has not been used that long. Several years of data in thousands of people is meaningful, but it does not make any medication risk-free, and it was not gathered at lower maintenance doses.

What “low dose” maintenance actually means

The FDA labels do set maintenance doses. For brand-name semaglutide for weight management (Wegovy), the label lists a maintenance dose of 2.4mg weekly (recommended) or 1.7mg, and allows people who have tolerated 2.4mg for at least 4 weeks to increase to a maximum of 7.2mg weekly if more weight reduction is clinically indicated.^[5] For brand-name tirzepatide for weight management (Zepbound), the labeled maintenance doses are 5, 10, or 15mg weekly.^[7] Both labels tell prescribers to consider response and tolerability when choosing a maintenance dose.

Low-dose or microdose maintenance usually means staying below those labeled maintenance doses. That is off-label: a provider using clinical judgment outside what the FDA reviewed. The idea is to find the lowest dose that holds your results with side effects you can live with.

There is no trial-established “low maintenance dose” for either medication, and no agreed percentage of the full dose that works for most people. Doses described as microdosing vary from one program to the next. Many lower-dose offerings use compounded semaglutide or tirzepatide. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products such as Wegovy or Zepbound. They may differ in formulation, purity, and potency.^[8]

If a lower dose interests you, a licensed provider decides whether it is appropriate and at what dose.

Why staying on low-dose maintenance makes sense

Weight maintenance: This is the primary purpose. The STEP 4 and SURMOUNT-4 trials showed that continuing the medication at the dose people had reached kept weight off on average. Whether lower doses do the same has not been formally studied; some providers use them based on clinical judgment, and results vary.

Metabolic benefits persist: Many of the metabolic improvements that happen during active weight loss (lower blood pressure, better glucose control, improved lipid profile) appear to depend on keeping the weight off. In the STEP 1 extension, they moved back toward baseline after people stopped treatment and regained weight.^[4] A maintenance dose that holds the weight may help keep them, though that has not been tested at lower doses.

Reduced food noise: GLP-1 medications act on appetite signaling, and many people describe quieter “food noise” while on them. How much of that remains at a lower dose varies by person.

Cardiovascular benefit potential: The SELECT trial showed cardiovascular benefit at semaglutide 2.4mg in people with existing heart disease. Whether lower maintenance doses provide the same benefit has not been studied. It is plausible that the weight maintenance itself drives part of the benefit, but this remains an area of active research.

What to consider before staying on maintenance

Cost: Maintenance is an ongoing cost, and how much a lower dose saves depends on the product and the program. Some programs price by dose; others charge the same at every dose. Compare the total cost: medication, dose changes, provider visits, labs, shipping, membership fees, and cancellation terms. Weigh that against what regaining the weight could mean for your health.

Side effects: A lower dose may mean fewer digestive side effects, but there is little data on side effects at doses below the labeled range, and individual experience varies. Nausea, constipation, and reduced appetite can persist, and they can affect quality of life. GLP-1 medications also carry warnings, including for pancreatitis, gallbladder problems, and, on the brand-name labels, a boxed warning about thyroid C-cell tumors seen in rodents.^[5][7] This is a conversation to have with your provider.

Duration of commitment: There is no clinical consensus on how long you should stay on low-dose maintenance. Some people continue indefinitely. Others taper and discontinue after a period of time. Some take breaks and restart if regain begins. None of these approaches has been formally studied. The choice depends on your goals, your biology, and your provider’s assessment of what keeps you stable.

Bone and muscle health: Weight loss, including weight loss on GLP-1 medications, can include loss of muscle and bone along with fat. How a lower maintenance dose affects this has not been studied. Ask your provider about monitoring, strength training, and protein intake to help preserve bone and muscle long-term.

The “blood pressure medication” analogy

Some providers frame long-term low-dose GLP-1 maintenance by comparing it to blood pressure medication.

Obesity and metabolic dysfunction are chronic conditions. They do not “get cured” by reaching a goal weight. The underlying biological drivers of appetite and metabolism persist. Just as blood pressure tends to rise again after you stop blood pressure medication, appetite and weight-gain biology tend to return after you stop GLP-1 medication.

If you take blood pressure medication indefinitely at the lowest effective dose, you are making a rational choice about managing a chronic condition. The same logic is often applied to GLP-1 maintenance.

This is a useful analogy for thinking about the decision. But it is not clinical equivalence. The evidence base, approval status, side effect profiles, and duration of use differ between the two classes of drugs. The analogy is useful as a mental model; it should not replace a conversation with your provider about your specific situation.

Who this approach works well for

Low-dose maintenance tends to come up if:

You have reached your goal weight on active treatment and want to talk about a lower dose rather than stopping entirely. You are concerned about the regain that the STEP 4 and SURMOUNT-4 data showed was common after stopping.

You experienced significant weight regain in the past when you stopped weight loss medications or programs. You want to avoid that cycle again.

A licensed provider determines that ongoing treatment, and the dose, is clinically appropriate for your health history and current status. This is the key decision.

The ongoing cost works for your budget. Cost is a legitimate barrier; ask each program for the total monthly cost at your dose before you commit.

What the long-term data says vs. what we do not yet know

What we know:

• Stopping GLP-1 medication led to weight regain for most participants in trials (STEP 4, STEP 1 extension, SURMOUNT-4).
• Continuing the medication at the dose people had reached maintained weight loss on average.
• In SELECT, semaglutide 2.4mg lowered major cardiovascular events over an average of about 3.3 years, with more people stopping because of side effects than on placebo.
• Lower doses are used off-label by some providers, but no trial has tested long-term outcomes or safety at those doses.

What we do not know:

• Whether lower maintenance doses have the same long-term safety profile as labeled doses (specific data does not exist).
• Whether lower maintenance doses provide the same cardiovascular benefits as labeled doses (not studied).
• The appropriate duration of maintenance dosing for any individual (this varies by person and is a provider decision).
• Long-term outcomes beyond the several years covered by current trials (this data will come from ongoing studies and real-world experience over time).

This reflects the fact that these medications are relatively new for weight management, and the long-term research is still being conducted. What we know supports continuing treatment for many people. What we do not yet know is worth discussing openly with a provider before you choose a dose.

What to check before using a low-dose GLP-1

If you have reached your goal weight and are weighing low-dose maintenance, bring these questions to whichever licensed provider you are considering. The answers tell you a lot about the plan, and about the program.

• What maintenance dose would you suggest for me, is it within the labeled range or below it, and how would we decide whether to adjust it?
• Is the medication an FDA-approved brand-name product or a compounded one? If compounded, which licensed pharmacy prepares it, and is it a 503A or 503B pharmacy?
• What is the total monthly cost at this dose, what does it include (visits, labs, shipping, any membership fee), and does it change if my dose changes?
• How often will you check in with me, and what lab work or monitoring is involved?
• What is the plan if my weight starts to come back, or if side effects continue?
• Can I lower the dose, pause, or stop later, and what are the program’s cancellation terms?

A licensed provider decides whether a prescription is appropriate, and at what dose. Do not change or stop a medication on your own. Transformation Health does not accept payment from providers. How we make money.

Citations

[1] Rubino D, et al. “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.” JAMA 2021;325(14):1414-1425. https://pubmed.ncbi.nlm.nih.gov/33755728/

[2] Aronne LJ, et al. “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.” JAMA 2024;331(1):38-48. https://pubmed.ncbi.nlm.nih.gov/38078870/

[3] Lincoff AM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine 2023;389(24):2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/

[4] Wilding JPH, et al. “Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.” Diabetes, Obesity and Metabolism 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/

[5] Novo Nordisk. WEGOVY (semaglutide) prescribing information, sections 2.2 and 5 and boxed warning. U.S. Food and Drug Administration, revised 06/2026, accessed 2026-10-16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf

[6] Marso SP, et al. “Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.” New England Journal of Medicine 2016;375(4):311-322. https://pubmed.ncbi.nlm.nih.gov/27295427/

[7] Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information, sections 2 and 5 and boxed warning. U.S. Food and Drug Administration, revised 08/2026, accessed 2026-10-16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf

[8] U.S. Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” Accessed 2026-10-16. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss